Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Under Fire: Beretta finds itself target of gun foes and shifting market (family-run for 500 years, firearm firm feels push to add products, partners)

Article Abstract:

Italian firearms manufacturer Fabbrica D'armi Pietro Beretta SpA is looking at the option of diversifying its business. The family-run organization that has been in existence for nearly 500 years is faced with several product-liability lawsuits in the United States that may cost millions in settlements. With sales totalling $226 million in 1997, Beretta has already begun to diverisfy its prduct line with the introduction of rifles and hunting-style clothing.

Author: Murray, Shailagh
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
Italy, Strategy & planning, Government regulation (cont), Small Arms Manufacturing, Small Arms, Cases, Firearms, Abstract, Firearms industry, Firearms industry and trade, Weapons industry, Fabbrica D'Armi Pietro Beretta S.p.A.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


U.S. consumer groups question use of free samples by drug makers

Article Abstract:

US consumer groups do not appreciate free samples of expensive new drugs because it gets patients, doctors and nurse practitioners used to prescribing this version rather than a less expensive generic version. Samples of drugs are expensive for drug companies but provide a high return on investment.

Author: Hensley, scott, Murray, Shailagh
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
Pharmaceutical preparations, Services development, Marketing, Public opinion, Samples (Merchandising), Samples (Products)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Schering targets biotech firms; drug maker looks to revive sales

Article Abstract:

Schering AG of Germany hopes to raise sales by its acquisition of smaller pharmaceutical companies, such as Diatide Inc, which makes nuclear medicines. Marketing rights to some Diatide products are shared by Nycomed Amersham Inc.

Author: Moore, Stephen D., Murray, Shailagh
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
Acquisitions & mergers, Germany, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Strategic alliances, Inorganic Chemicals, Other Basic Inorganic Chemical Manufacturing, Mergers, acquisitions and divestments, Licensing agreements, Chemical industry, Schering AG, Inorganic compounds, Diatide Inc., Nycomed Amersham Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Statistical Data Included, Pharmaceutical industry, Drugs
Similar abstracts:
  • Abstracts: Jador postpones its share offering for fourth time. ETF plans IPO to fund start-ups in web businesses. Danish Tech IPO is likely to create lively demand
  • Abstracts: Syzygy braces for an IPO in tough market for Net firms. Deutsche Telekom's profit falls 45%. Deutsche Telekom cuts price of T-Online's IPO shares
  • Abstracts: SEC probes whether 2 firms manipulated treasury market. E*Trade fixes flaw that left accounts open to hackers
  • Abstracts: Nokia's profit warning stuns markets around the world. SEB, Swedbank agree to 7.9 billion euros merger. Who Needs WAP? Short Message Service Can Fulfill Demand for Wireless Web Access. Providing Better Security for Mobile Online Transactions
  • Abstracts: World Access is set to trade shares for Teldafax stake. Sale of Sprint shares will put small dent in sellers' debt
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.